PRIMARY BILIARY CHOLANGITIS
Clinical trials for PRIMARY BILIARY CHOLANGITIS explained in plain language.
Never miss a new study
Get alerted when new PRIMARY BILIARY CHOLANGITIS trials appear
Sign up with your email to follow new studies for PRIMARY BILIARY CHOLANGITIS, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New drug aims to stop liver decline in PBC patients with cirrhosis
Disease control Recruiting nowThis Phase 3 trial tests whether seladelpar, a daily pill, can improve outcomes for people with primary biliary cholangitis (PBC) who also have compensated cirrhosis. About 318 adults will receive either seladelpar or a placebo for up to 36 months. The study tracks serious events…
Matched conditions: PRIMARY BILIARY CHOLANGITIS
Phase: PHASE3 • Sponsor: Gilead Sciences • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
New drug elafibranor tested in everyday use for rare liver disease
Disease control Recruiting nowThis study follows about 424 people with primary biliary cholangitis (PBC) who are taking elafibranor as part of their normal care. Researchers will track how well the drug controls liver damage and symptoms like itching over 5 years. The goal is to see if elafibranor works safel…
Matched conditions: PRIMARY BILIARY CHOLANGITIS
Sponsor: Ipsen • Aim: Disease control
Last updated Jun 27, 2026 12:39 UTC
-
New combo therapy offers hope for liver disease patients not helped by standard drug
Disease control Recruiting nowThis study is for adults with primary biliary cholangitis (a chronic liver disease) who also have cirrhosis and did not respond well to the usual treatment, ursodeoxycholic acid. Researchers want to see if adding fenofibrate to their treatment can improve liver health by normaliz…
Matched conditions: PRIMARY BILIARY CHOLANGITIS
Phase: PHASE2, PHASE3 • Sponsor: Xijing Hospital of Digestive Diseases • Aim: Disease control
Last updated Jun 27, 2026 08:10 UTC
-
New combo therapy aims to help PBC patients who Don't respond to standard treatment
Disease control Recruiting nowThis Phase 3 trial tests whether adding fenofibrate to standard ursodeoxycholic acid (UDCA) therapy improves liver health in people with primary biliary cholangitis (PBC) who do not respond well to UDCA alone. About 150 adults will receive either the combination or a placebo plus…
Matched conditions: PRIMARY BILIARY CHOLANGITIS
Phase: PHASE3 • Sponsor: Xijing Hospital of Digestive Diseases • Aim: Disease control
Last updated Jun 27, 2026 08:09 UTC
-
New hope for rare liver disease: phase 3 trial of CS0159 launches
Disease control Recruiting nowThis study tests a new drug called CS0159 in 135 adults with primary biliary cholangitis (PBC), a chronic liver disease. Participants must have had an inadequate response or intolerance to the standard treatment UDCA. The trial compares CS0159 to a placebo over 52 weeks to see if…
Matched conditions: PRIMARY BILIARY CHOLANGITIS
Phase: PHASE3 • Sponsor: Cascade Pharmaceuticals, Inc • Aim: Disease control
Last updated Jun 27, 2026 08:07 UTC
-
New pill aims to stop the relentless itch of a rare liver disease
Symptom relief Recruiting nowThis study tests an experimental drug called volixibat for people with primary biliary cholangitis (PBC) who suffer from severe itching. The trial will involve 260 adults and compare volixibat against a placebo to see if it safely reduces itch severity and improves quality of lif…
Matched conditions: PRIMARY BILIARY CHOLANGITIS
Phase: PHASE2 • Sponsor: Mirum Pharmaceuticals, Inc. • Aim: Symptom relief
Last updated Jun 27, 2026 12:33 UTC
-
Austrian PBC registry aims to unlock secrets of rare liver disease
Knowledge-focused Recruiting nowThis study is a registry that will follow 500 people with primary biliary cholangitis (PBC) in Austria. Researchers will collect medical data and optional blood or liver samples to learn how the disease progresses and what complications arise. No new treatment is being tested; th…
Matched conditions: PRIMARY BILIARY CHOLANGITIS
Sponsor: Medical University of Vienna • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:35 UTC
-
Gene hunt for mysterious adult liver disease
Knowledge-focused Recruiting nowThis study is using advanced whole-genome sequencing to find hidden genetic causes of cholestatic liver disease in adults whose condition remains unexplained after standard tests. Researchers will compare the DNA of 60 affected adults to a large group of healthy controls. The goa…
Matched conditions: PRIMARY BILIARY CHOLANGITIS
Phase: NA • Sponsor: Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:01 UTC
-
3000-Patient study aims to predict PBC outcomes from blood tests
Knowledge-focused Recruiting nowThis study looks at 3,000 people with primary biliary cholangitis (PBC) to see how their blood levels of alkaline phosphatase (ALP) after treatment relate to their risk of liver complications. The goal is to create a model that predicts who will do well and who might need stronge…
Matched conditions: PRIMARY BILIARY CHOLANGITIS
Sponsor: RenJi Hospital • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:10 UTC
-
Blood test could spot Immunotherapy-Linked liver damage
Knowledge-focused Recruiting nowThis study aims to identify specific blood markers that can distinguish hepatitis caused by immune checkpoint inhibitors from other types of autoimmune hepatitis. Researchers will collect blood samples and liver tissue from 60 adults receiving immunotherapy. The goal is to improv…
Matched conditions: PRIMARY BILIARY CHOLANGITIS
Sponsor: University Hospital, Montpellier • Aim: Knowledge-focused
Last updated Jun 27, 2026 07:58 UTC